1 / 31

Understanding How IL-23p19 Inhibitors Work in Psoriasis

Understanding How IL-23p19 Inhibitors Work in Psoriasis. This program will include a discussion of data some of which has only been presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Introduction.

othello
Download Presentation

Understanding How IL-23p19 Inhibitors Work in Psoriasis

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Understanding How IL-23p19 Inhibitors Work in Psoriasis

  2. This program will include a discussion of data some of which has only been presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

  3. Introduction

  4. The Role of IL-23 in the Psoriasis Disease Cascade

  5. The Role of IL-23 in the Psoriasis Disease Cascade (cont)

  6. Therapeutic Strategy in Psoriasis -- Difference Between Upstream and Downstream Inhibition

  7. IL-23 Inhibitors in Moderate-to-Severe Psoriasis -- Approved and in Latest Development Stages

  8. Difference Between Ustekinumab (IL-12/IL-23p40 Inhibitor) and IL-23p19 Inhibitors

  9. Guselkumab vs Adalimumab: VOYAGE-1 and VOYAGE-2

  10. Guselkumab vs Secukinumab: ECLIPSE

  11. Tildrakizumab vs Etanercept: reSURFACE-1 and reSURFACE-2

  12. How Do Guselkumab, Tildrakizumab, and Ustekinumab Compare? -- Expert Perspective

  13. Risankizumab vs Ustekinumab -- ultIMMA & Risankizumab vs Adalimumab -- IMMvent

  14. PASI 90/100 as Endpoints -- Expert Perspective

  15. Mirikizumab: PASI 90 at Week 16 Phase 2 Study

  16. Ranking of IL-23p19 Inhibitors -- Expert Perspective

  17. What Are the Differences Between IL-23p19 and IL-17 Inhibitors?

  18. IL-23p19 Inhibitors -- Insights on Remission and Disease Modifying Effect

  19. IL-23p19 Inhibitors -- Insights on Remission and Disease Modifying Effect (cont)

  20. Durability of IL-23p19 Inhibitors

  21. Difficult to Treat Psoriasis -- Ixekizumab IXORA-S Study in Nail Psoriasis

  22. Difficult to Treat Psoriasis -- Guselkumab NAPSI and f-PGA (VOYAGE-2)

  23. Difficult to Treat Psoriasis -- Risankizumab

  24. Additional Indications Under Investigation for IL-23p19 Inhibitors

  25. PASI 90/PASI 100 and Quality of Life -- What Is the Value for Patients?

  26. Experience Using IL-23p19 Inhibitors -- Expert Perspective

  27. Concluding Remarks

  28. Concluding Remarks (cont)

  29. Abbreviations

  30. Abbreviations (cont)

  31. Abbreviations (cont)

More Related